Expensify Insider Cashes Out with $349,930 Stock Sale
December 12, 2023
🌥️Trending News
Expensify ($NASDAQ:EXFY), a leading expense management company for businesses and individuals, recently made news after an insider sale of shares valued at $349,930 was filed with the U.S. Securities and Exchange Commission. This indicates that the sale was not made due to any insider information, but rather as part of Valler’s pre-scheduled trading plan. In spite of this sale, Expensify remains a strong company.
Its stock has been performing well, and its customer base continues to expand. With their continued growth and success, it’s likely that the Expensify Insider will continue to benefit from their investments in the future.
Price History
On Monday, EXPENSIFY saw a significant stock dip. The stock opened at $2.5 and closed at a 6.5% drop from the previous closing price of $2.4, settling at $2.3.
However, despite this sharp drop in share price, one insider was able to cash out with a substantial stock sale. It is not yet known what the insider’s motivation for this sale was or what they planned to do with the proceeds. The immediate drop in share price could be attributed to the sheer number of shares sold by the insider; however, it is still unclear what the long-term implications of this sale will be. Investors will be watching closely to determine how much further EXPENSIFY’s stock may drop due to this sale and whether or not it will bounce back. Expensify_Insider_Cashes_Out_with_349930_Stock_Sale”>Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Expensify. More…
| Total Revenues | Net Income | Net Margin |
| 158.95 | -37.65 | -23.7% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Expensify. More…
| Operations | Investing | Financing |
| 8.75 | -5.66 | -16.55 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Expensify. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 212.31 | 117.26 | 1.14 |
Key Ratios Snapshot
Some of the financial key ratios for Expensify are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 28.2% | – | -17.5% |
| FCF Margin | ROE | ROA |
| 1.9% | -17.9% | -8.2% |
Analysis
As GoodWhale, our analysis of EXPENSIFY’s financials has classified them as a ‘rhino’, a type of company that has achieved moderate revenue or earnings growth. This makes EXPENSIFY an attractive investment opportunity for investors who are looking for companies with sustainable growth potential and good financial health. EXPENSIFY has a high health score of 8 out of 10 with regard to its cashflows and debt, indicating that the company is capable of paying off its current liabilities and funding future operations without significant debt. Furthermore, EXPENSIFY is strong in asset, growth, medium in profitability and weak in dividend, which makes it an ideal investment for investors looking for an opportunity with good returns and growth potential. Expensify_Insider_Cashes_Out_with_349930_Stock_Sale”>More…
Peers
Its main competitors are Thinkific Labs Inc, IODM Ltd, and DocuSign Inc.
– Thinkific Labs Inc ($TSX:THNC)
Thinkific Labs Inc is a Canadian company that provides an online course platform for entrepreneurs, businesses, and individuals. The company was founded in 2012 and is headquartered in Vancouver, British Columbia. As of 2022, the company has a market cap of 281.34M and a ROE of -21.73%. The company’s platform allows users to create, market, and sell their own online courses. The company offers a variety of features, including course creation tools, video hosting, payment processing, and course marketing tools.
– IODM Ltd ($ASX:IOD)
Period is a medical technology company that develops and commercializes innovative products for the treatment of heavy menstrual bleeding, or menorrhagia. The company’s flagship product, the Menstrual Flow Reducing Device, is a non-hormonal, non-surgical device that is placed in the uterine cavity to reduce menstrual blood flow. Period’s products are backed by over 20 years of clinical data and have been used by over 100,000 women worldwide. The company’s products are available in over 30 countries and its products are distributed through a network of over 1,000 distributors.
– DocuSign Inc ($NASDAQ:DOCU)
DocuSign Inc is a company that provides electronic signature technology and digital transaction management services. It has a market cap of 10.09B as of 2022 and a Return on Equity of -15.28%. The company enables its customers to electronically sign, send, and manage documents. It offers eSignature, a cloud-based electronic signature solution that allows users to sign, send, and manage documents; and DocuSign CLM, a cloud-based contract lifecycle management solution that enables users to manage the entire contracting process from start to finish.
Summary
Expensify, a financial management platform, recently had an insider selling off $349,930 worth of their shares, as disclosed in a recent SEC filing. This sale has caused the stock price to drop on the same day. Investors should be aware of this news and consider its potential implications when making investment decisions. Analyzing the financial health of the company is essential in order to get a better understanding of its current value.
It is also important to look at past performance and make sure that their future outlook still looks good. Further research into other factors such as management team and competitive market position should be conducted to thoroughly evaluate Expensify as an investment opportunity.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
